{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:36:46Z","timestamp":1783769806907,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.parkreldis.2019.06.022","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T08:56:11Z","timestamp":1561452971000},"page":"224-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson's disease"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7448-1041","authenticated-orcid":false,"given":"Chien-Tai","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-4460","authenticated-orcid":false,"given":"Lung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Nien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2019.06.022_bib1","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.06.022_bib2","first-page":"39","article-title":"Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective","volume":"2","author":"Brocks","year":"1999","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.06.022_bib3","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008862","article-title":"The history of Parkinson's disease: early clinical descriptions and neurological therapies","volume":"1","author":"Goetz","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.parkreldis.2019.06.022_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejphar.2015.01.030","article-title":"Management of Parkinson\u05f3s disease: current and future pharmacotherapy","volume":"750","author":"Kakkar","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.parkreldis.2019.06.022_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00002512-199303040-00004","article-title":"The problems of anticholinergic adverse effects in older patients","volume":"3","author":"Feinberg","year":"1993","journal-title":"Drugs Aging"},{"issue":"7539","key":"10.1016\/j.parkreldis.2019.06.022_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2019.06.022_bib7","first-page":"361","article-title":"Anticholinergic drugs and risk of dementia: case-control study","author":"Richardson","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.parkreldis.2019.06.022_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e2986","article-title":"Cholinesterase inhibitors and memantine for symptomatic treatment of dementia","volume":"344","author":"Rodda","year":"2012","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.parkreldis.2019.06.022_bib9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/ene.12950","article-title":"The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study","volume":"23","author":"Prakash","year":"2016","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2019.06.022_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jagp.2012.12.007","article-title":"Prevalence of Parkinson disease and Parkinson disease dementia in community nursing homes","volume":"21","author":"Hoegh","year":"2013","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"4","key":"10.1016\/j.parkreldis.2019.06.022_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.celrep.2015.09.034","article-title":"Striatal cholinergic interneurons control motor behavior and basal ganglia function in experimental parkinsonism","volume":"13","author":"Maurice","year":"2015","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.parkreldis.2019.06.022_bib12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2019.06.022_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1715163514529740","article-title":"Parkinson's disease guidelines for pharmacists","volume":"147","author":"Patel","year":"2014","journal-title":"Can. Pharm. J."},{"issue":"1","key":"10.1016\/j.parkreldis.2019.06.022_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1073\/pnas.012467899","article-title":"Functional MRI detection of pharmacologically induced memory impairment","volume":"99","author":"Sperling","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Pt 6","key":"10.1016\/j.parkreldis.2019.06.022_bib15","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/brain\/117.6.1377","article-title":"Effects of cholinergic blockade on language in healthy young women. Implications for the cholinergic hypothesis in dementia of the Alzheimer type","volume":"117","author":"Aarsland","year":"1994","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.parkreldis.2019.06.022_bib16","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.06.022_bib17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1212\/WNL.0000000000002839","article-title":"Cholinergic and perfusion brain networks in Parkinson disease dementia","volume":"87","author":"Colloby","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2019.06.022_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/jnnp.42.1.59","article-title":"Regional impairment of cerebral oxidative metabolism in Parkinson's disease","volume":"42","author":"Lenzi","year":"1979","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.parkreldis.2019.06.022_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.10639","article-title":"Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs","volume":"54","author":"Perry","year":"2003","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2019.06.022_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","article-title":"Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study","volume":"81","author":"Ehrt","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2019.06.022_bib21","first-page":"341","article-title":"Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors","author":"Ritchie","year":"2010","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.parkreldis.2019.06.022_bib22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.parkreldis.2012.04.007","article-title":"Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson's disease","volume":"18","author":"Mochio","year":"2012","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2019.06.022_bib23","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1212\/WNL.0000000000005903","article-title":"Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease","volume":"91","author":"Hacker","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.parkreldis.2019.06.022_bib24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","article-title":"Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial","volume":"74","author":"Bond","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2019.06.022_bib25","series-title":"Movement Disorders: A Video Atlas: A Video Atlas","first-page":"8","article-title":"Tremor-dominant Parkinson's disease","author":"Bhidayasiri","year":"2012"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019302858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802019302858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:13:37Z","timestamp":1762370017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802019302858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":25,"alternative-id":["S1353802019302858"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.06.022","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2019.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}